Skip to main content

Ocriplasmin Recommended for Vitreomacular Adhesions


July 27, 2012 — An advisory committee to the US Food and Drug Administration (FDA) voted July 26 to recommend ocriplasmin (Jetrea, ThromboGenics, Inc) 125 μg intravitreal injection for the treatment of symptomatic vitreomacular adhesions (sVMAs), including macular hole.
The committee voted unanimously to recommend approval of ocriplasmin for the treatment of VMAs, and 7 to 3 in favor of recommending approval for treatment of macular holes. "I thought the anatomic data was very favorable," Stephen S. Feman, MD, MPH, a professor at Saint Louis University School of Medicine in Missouri and voting committee member, said during the advisory meeting.
Symptomatic VMAs result from incomplete separation of the vitreous from the macula and can be progressive and result in blindness. At this time, the only treatment option is vitrectomy, a major surgical procedure that is usually postponed until late in the disorder because of the potential risks and difficult recovery period. Ocriplasmin is the first pharmacologic treatment for symptomatic VMAs and could improve outcomes by making treatment available earlier.
Ocriplasmin is a recombinant truncated form of the human serine protease plasmin with retained enzymatic activity that acts on collagen, fibronectin, and laminin to liquefy the vitreous, resulting in its detachment from the macula.
The committee discussed data from 2 randomized, phase 3, placebo-controlled studies, TG-MV-006 and TG-MV-007. Each study had 326 participants, and a total of 652 eyes were injected.
The studies enrolled patients with sVMA, which was described as vitreomacular traction with or without a full-thickness macular hole.
Patients were seen for 7 visits during a 6-month period: at baseline and on injection day (day 0), postinjection day 7, postinjection day 14, postinjection day 28, postinjection month 3, and postinjection month 6.
Efficacy
The primary efficacy endpoint was the proportion of patients whose focal VMA resolved without surgery at day 28 postinjection, as determined by masked central reading center optical coherence tomography evaluation.
The secondary efficacy endpoint was the proportion of patients who had total posterior vitreous detachment at day 28, as determined by masked investigator assessment of B-scan ultrasound.
Primary endpoints were achieved in each study, and statistically significantly higher VMA resolution rates were seen at day 28 in patients who received a single injection of 125 μg ocriplasmin compared with placebo.
In study TG-MV-006, 13.1% (n = 107) of patients who received placebo and 27.9% (n = 219) of patients who received ocriplasmin met primary efficacy endpoints.
In study TG-MV-007, 6.2% (n = 81) of patients who received placebo and 25.3% (n = 245) of patients who received ocriplasmin met primary efficacy endpoints.
Safety
Data from a total of 7 completed studies, including TG-MV-006 and TG-MV-007, also were analyzed for safetyas well. Of note, 9 of 976 ocriplasmin-treated patients experienced temporary, postinjection serious and/or severe adverse events that involved acute vision decrease within 24 hours of injection. Vision returned to at least pretreatment levels (median time, 2 weeks) in all but 1 patient, whose vision decrease was considered to be related to concurrent retinal disease. The reasons for this are unclear.
A total of 8 patients from the 7 studies died; 6 were in the treatment group and 2 were in the placebo group. None of the deaths were related to treatment.
"The majority of patients who receive this drug will not get benefit from the drug, and I think that that needs to be very clearly stated. If the drug is approved, it must be very clearly stated in labeling.... Even though there is efficacy benefit over risk...the majority of patients will not see a benefit from this drug," said Lynn Gordon, MD, PhD, a professor of ophthalmology at Jules Stein Eye Institute and associate dean of diversity affairs at David Geffen School of Medicine at the University of California, Los Angeles, and voting committee member, said during the advisory meeting.
"I agree with [Dr. Gordon's] concerns, but I suspect that the sponsor will look at, and the ophthalmology community will identify, which patients have a higher potential for benefit with this treatment," said Susan MacDonald, MD, director of comprehensive ophthalmology and assistant professor at Tufts University School of Medicine, Boston, Massachusetts, also a voting committee member, said during the advisory meeting.
"I believe that if you can reduce the number of people that need vitrectomy by 25% by using this medication, you're really making a benefit to mankind," said Dr. Feman.
No relevant financial relationships were disclosed by the voting committee members. The industry representative is employed by Forest Laboratories.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more